Chemioterapia dose-dense nell'anziano affetto da linfoma non Hodgkin: La schedula CEOPm consente il mantenimento di una adeguata dose-intensity

Translated title of the contribution: Age-tailored CHOP schedule (CEOPm) allows to maintain the dose intensity in aggressive non Hodgkin lymphomas of the elderly

Antonio Rea, G. Gadaleta-Caldarola, M. Colangelo, S. Infusino, A. Filice, C. Mastroianni, C. Sandomenico, C. Manfredi, S. Palazzo

Research output: Contribution to journalArticle

Abstract

Patients with associated morbidities are usually excluded from phase III trials on NHL therapy in the elderly, so that results obtained often cannot be reproduced in routine clinical practice. The CHOP, as well as CHOP-14 schedule with dose dense-intensification, cannot be administered to elderly patients with associated morbidities or severe reduction in liver and kidney functionality. In order to guarantee an adequate dose intensity of most active drugs to these patients, we formulated a modified bimonthly CHOP schedule, based on the reduction of single delivered dose of each drug and on shorter intervals between cycles (dose-dense intensification). We enrolled to treatment 10 patients (7 males and 3 females) aged between 71 and 82 years, affected by intermediate-high grade NHL, stage III and IV. Nine out of them were affected by two or more pathologic conditions; we found high IPI score in four patients. All patients completed the planned 12 courses of chemotherapy. We observed 7 complete responses, 2 partial responses and 1 progression of disease. Grade 2-3 neutropenia was observed in four patients and grade 2 anemia in two patients. We concluded that this modality of treatment might be useful in elderly and/or frail people affected by NHL; however a larger study should be performed.

Original languageItalian
Pages (from-to)55-61
Number of pages7
JournalGeriatric and Medical Intelligence
Volume15
Issue number1
Publication statusPublished - Jan 2006

Fingerprint

Non-Hodgkin's Lymphoma
Appointments and Schedules
Morbidity
Frail Elderly
Neutropenia
Pharmaceutical Preparations
Disease Progression
Anemia
Therapeutics
Kidney
Drug Therapy
Liver

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Rea, A., Gadaleta-Caldarola, G., Colangelo, M., Infusino, S., Filice, A., Mastroianni, C., ... Palazzo, S. (2006). Chemioterapia dose-dense nell'anziano affetto da linfoma non Hodgkin: La schedula CEOPm consente il mantenimento di una adeguata dose-intensity. Geriatric and Medical Intelligence, 15(1), 55-61.

Chemioterapia dose-dense nell'anziano affetto da linfoma non Hodgkin : La schedula CEOPm consente il mantenimento di una adeguata dose-intensity. / Rea, Antonio; Gadaleta-Caldarola, G.; Colangelo, M.; Infusino, S.; Filice, A.; Mastroianni, C.; Sandomenico, C.; Manfredi, C.; Palazzo, S.

In: Geriatric and Medical Intelligence, Vol. 15, No. 1, 01.2006, p. 55-61.

Research output: Contribution to journalArticle

Rea, A, Gadaleta-Caldarola, G, Colangelo, M, Infusino, S, Filice, A, Mastroianni, C, Sandomenico, C, Manfredi, C & Palazzo, S 2006, 'Chemioterapia dose-dense nell'anziano affetto da linfoma non Hodgkin: La schedula CEOPm consente il mantenimento di una adeguata dose-intensity', Geriatric and Medical Intelligence, vol. 15, no. 1, pp. 55-61.
Rea, Antonio ; Gadaleta-Caldarola, G. ; Colangelo, M. ; Infusino, S. ; Filice, A. ; Mastroianni, C. ; Sandomenico, C. ; Manfredi, C. ; Palazzo, S. / Chemioterapia dose-dense nell'anziano affetto da linfoma non Hodgkin : La schedula CEOPm consente il mantenimento di una adeguata dose-intensity. In: Geriatric and Medical Intelligence. 2006 ; Vol. 15, No. 1. pp. 55-61.
@article{10620c970ecf48a0a2727c8a71da059f,
title = "Chemioterapia dose-dense nell'anziano affetto da linfoma non Hodgkin: La schedula CEOPm consente il mantenimento di una adeguata dose-intensity",
abstract = "Patients with associated morbidities are usually excluded from phase III trials on NHL therapy in the elderly, so that results obtained often cannot be reproduced in routine clinical practice. The CHOP, as well as CHOP-14 schedule with dose dense-intensification, cannot be administered to elderly patients with associated morbidities or severe reduction in liver and kidney functionality. In order to guarantee an adequate dose intensity of most active drugs to these patients, we formulated a modified bimonthly CHOP schedule, based on the reduction of single delivered dose of each drug and on shorter intervals between cycles (dose-dense intensification). We enrolled to treatment 10 patients (7 males and 3 females) aged between 71 and 82 years, affected by intermediate-high grade NHL, stage III and IV. Nine out of them were affected by two or more pathologic conditions; we found high IPI score in four patients. All patients completed the planned 12 courses of chemotherapy. We observed 7 complete responses, 2 partial responses and 1 progression of disease. Grade 2-3 neutropenia was observed in four patients and grade 2 anemia in two patients. We concluded that this modality of treatment might be useful in elderly and/or frail people affected by NHL; however a larger study should be performed.",
keywords = "Dose-density, Dose-intensity, Elderly, NHL",
author = "Antonio Rea and G. Gadaleta-Caldarola and M. Colangelo and S. Infusino and A. Filice and C. Mastroianni and C. Sandomenico and C. Manfredi and S. Palazzo",
year = "2006",
month = "1",
language = "Italian",
volume = "15",
pages = "55--61",
journal = "Geriatric and Medical Intelligence",
issn = "1121-8460",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Chemioterapia dose-dense nell'anziano affetto da linfoma non Hodgkin

T2 - La schedula CEOPm consente il mantenimento di una adeguata dose-intensity

AU - Rea, Antonio

AU - Gadaleta-Caldarola, G.

AU - Colangelo, M.

AU - Infusino, S.

AU - Filice, A.

AU - Mastroianni, C.

AU - Sandomenico, C.

AU - Manfredi, C.

AU - Palazzo, S.

PY - 2006/1

Y1 - 2006/1

N2 - Patients with associated morbidities are usually excluded from phase III trials on NHL therapy in the elderly, so that results obtained often cannot be reproduced in routine clinical practice. The CHOP, as well as CHOP-14 schedule with dose dense-intensification, cannot be administered to elderly patients with associated morbidities or severe reduction in liver and kidney functionality. In order to guarantee an adequate dose intensity of most active drugs to these patients, we formulated a modified bimonthly CHOP schedule, based on the reduction of single delivered dose of each drug and on shorter intervals between cycles (dose-dense intensification). We enrolled to treatment 10 patients (7 males and 3 females) aged between 71 and 82 years, affected by intermediate-high grade NHL, stage III and IV. Nine out of them were affected by two or more pathologic conditions; we found high IPI score in four patients. All patients completed the planned 12 courses of chemotherapy. We observed 7 complete responses, 2 partial responses and 1 progression of disease. Grade 2-3 neutropenia was observed in four patients and grade 2 anemia in two patients. We concluded that this modality of treatment might be useful in elderly and/or frail people affected by NHL; however a larger study should be performed.

AB - Patients with associated morbidities are usually excluded from phase III trials on NHL therapy in the elderly, so that results obtained often cannot be reproduced in routine clinical practice. The CHOP, as well as CHOP-14 schedule with dose dense-intensification, cannot be administered to elderly patients with associated morbidities or severe reduction in liver and kidney functionality. In order to guarantee an adequate dose intensity of most active drugs to these patients, we formulated a modified bimonthly CHOP schedule, based on the reduction of single delivered dose of each drug and on shorter intervals between cycles (dose-dense intensification). We enrolled to treatment 10 patients (7 males and 3 females) aged between 71 and 82 years, affected by intermediate-high grade NHL, stage III and IV. Nine out of them were affected by two or more pathologic conditions; we found high IPI score in four patients. All patients completed the planned 12 courses of chemotherapy. We observed 7 complete responses, 2 partial responses and 1 progression of disease. Grade 2-3 neutropenia was observed in four patients and grade 2 anemia in two patients. We concluded that this modality of treatment might be useful in elderly and/or frail people affected by NHL; however a larger study should be performed.

KW - Dose-density

KW - Dose-intensity

KW - Elderly

KW - NHL

UR - http://www.scopus.com/inward/record.url?scp=33749607068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749607068&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:33749607068

VL - 15

SP - 55

EP - 61

JO - Geriatric and Medical Intelligence

JF - Geriatric and Medical Intelligence

SN - 1121-8460

IS - 1

ER -